The FDA wrote that it observed “serious violations” of reporting requirements during an inspection at a Novo facility in early 2025.
FDA warns Novo Nordisk over failure to report GLP-1 deaths, adverse side effects
Welcome to LJ News Opinions, where breaking news stories have captivated us for over 20 years.
Join us in this journey of sharing points of view about the news – read, react, engage, and unleash your opinion!